Myriad Genetics grants Vishal Sikri 53,236 stock options

The EVP, Commercial’s 53,236-option award becomes exercisable in full on November 6, 2029, subject to continued service through that date.

Available on EDGAR 11/09/2026 - 04:14 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Myriad Genetics granted EVP, Commercial Vishal Sikri a one-time retention award of 53,236 non-qualified stock options on November 6, 2026. Each option has a $5.92 exercise price, equal to the common stock’s closing price on the grant date. The options vest and become exercisable in full on November 6, 2029, subject to Sikri’s continued service through that date and the plan and award agreement terms; they expire November 6, 2036. His reported direct option position after the grant was 53,236 options.

Insider Trade Summary

Grant/Award: 53,236 shares

Grant/Award 1 txn

Insider Sikri Vishal

Role EVP, Commercial

Type	Security	Shares	Price	Value
Grant/Award	Time-Based Stock Option F1, F2	53,236	$0.00	$0.00

Holdings After Transaction: Time-Based Stock Option — 53,236 options (Direct)

Footnotes (2)

1. F1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.
2. F2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.

Key Figures

Stock options granted: 53,236 options Underlying common shares: 53,236 shares Exercise price: $5.92 per share +3 more

6 metrics

Stock options granted 53,236 options One-time retention award granted November 6, 2026

Underlying common shares 53,236 shares Shares underlying the options

Exercise price $5.92 per share Equal to the common stock closing price on the grant date

Vesting and exercisability date November 6, 2029 Options vest and become exercisable in full, subject to continued service

Expiration date November 6, 2036 Expiration date of the options

Direct option position after grant 53,236 options Reported position following the transaction

Key Terms

non-qualified stock option, retention award, vests, exercise price

4 terms

non-qualified stock option financial

"one-time non-qualified stock option granted as a retention award"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

retention award financial

"granted as a retention award"

vests financial

"option vests and becomes exercisable in full"

exercise price financial

"The exercise price equals the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did MYGN EVP, Commercial Vishal Sikri receive?

Vishal Sikri, Myriad Genetics’ EVP, Commercial, received 53,236 non-qualified stock options as a one-time retention award on November 6, 2026. The options cover 53,236 shares of common stock, and his reported direct option position after the grant was 53,236 options.

When do MYGN’s options vest and become exercisable?

The options vest and become exercisable in full on November 6, 2029, subject to Sikri’s continued service through that date and the terms and conditions of the 2026 Employee, Director and Consultant Equity Incentive Plan and the applicable award agreement.

What are the exercise price and expiration date of MYGN’s option award?

The options have an exercise price of $5.92 per share and an expiration date of November 6, 2036. The exercise price equals Myriad Genetics’ common stock closing price on the November 6, 2026 grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sikri Vishal

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Commercial

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Time-Based Stock Option(1)	$5.92(2)	11/06/2026		A		53,236		11/06/2029	11/06/2036	Common Stock	53,236	$0	53,236	D

Explanation of Responses:

1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.

2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.

Remarks:

	By: Justin Hunter For: Vishal Sikri	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)